Stockscreener 앱 받기
4.95
2.94%
-0.15
시간 외 거래:
4.95
전일 마감가:
$5.10
열려 있는:
$5.1
하루 거래량:
896.60K
Relative Volume:
0.94
시가총액:
$260.84M
수익:
-
순이익/손실:
$-14.14M
주가수익비율:
-5.3804
EPS:
-0.92
순현금흐름:
$-12.64M
1주 성능:
-6.25%
1개월 성능:
-10.97%
6개월 성능:
+94.12%
1년 성능:
+115.22%
1일 변동 폭
$4.935
$5.29
1주일 범위
$4.935
$5.58
52주 변동 폭
$1.34
$7.73
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
IMMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
4.95 | 268.75M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Swing Trade: Can Immix Biopharma Inc stock surprise with earnings upsidePortfolio Update Report & Consistent Profit Alerts - moha.gov.vn
Why Immix Biopharma Inc stock remains undervaluedJuly 2025 Patterns & Fast Exit and Entry Trade Guides - moha.gov.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 27.5% in December - MarketBeat
Immix Biopharma (NASDAQ:IMMX) & Athira Pharma (NASDAQ:ATHA) Critical Survey - Defense World
Immix Biopharma (IMMX) price target increased by 50.00% to 12.24 - MSN
Is Immix Biopharma Inc. stock positioned well for digital economyLong Setup & Fast Exit and Entry Strategy Plans - Улправда
Immix Biopharma (IMMX) Price Target Increased by 50.00% to 12.24 - Nasdaq
Is Immix Biopharma Inc. stock resilient to inflation2025 Growth vs Value & Accurate Buy Signal Notifications - Улправда
Why Immix Biopharma Inc. stock remains on buy listsPortfolio Return Report & Precise Swing Trade Entry Alerts - DonanımHaber
Why Immix Biopharma Inc. stock remains undervaluedJuly 2025 Outlook & High Return Stock Watch Alerts - DonanımHaber
What momentum indicators show for Immix Biopharma Inc. stock2025 Stock Rankings & Weekly Chart Analysis and Trade Guides - Улправда
Is Immix Biopharma Inc. stock positioned for long term growth2025 Retail Activity & Free Risk Controlled Daily Trade Plans - DonanımHaber
What hedge fund activity signals for Immix Biopharma Inc. stock2025 Sector Review & Free Risk Controlled Daily Trade Plans - ulpravda.ru
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - Defense World
Immix Biopharma Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in
Trendlines Converge — Decision Point for Tirupati Starch and Chemicals LimitedTake Profit Strategies & Compound Your Gains With Quality Stocks - earlytimes.in
Immix Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
Aug Summary: Will Immix Biopharma Inc stock benefit from infrastructure spending2025 Macro Impact & Verified Entry Point Detection - moha.gov.vn
FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst - MarketBeat
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares - Investing.com India
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha
Immix Biopharma Stock Surges 70%, With A 6-Day Winning Spree - Trefis
Immix Biopharma CFO Gabriel Morris buys $5k in shares By Investing.com - Investing.com Canada
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares By Investing.com - Investing.com Canada
Immix Biopharma CFO Gabriel Morris buys $5k in shares - Investing.com
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright - Investing.com Australia
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright By Investing.com - Investing.com South Africa
IMMX Analyst Rating Update: HC Wainwright Raises Price Target to - GuruFocus
Immix Biopharma closes $93.7 million public offering By Investing.com - Investing.com Canada
Immix Biopharma closes $93.7 million public offering - Investing.com
Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants - marketscreener.com
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Immix Biopharma prices $100M equity raise via common stock and warrant offering - MSN
Taking the lead: Immix Biopharma Inc (IMMX) - setenews.com
Immix Biopharma — Promising NEXICART-2 data; runway extended - Smartkarma
Immix Biopharma Enters Underwriting Agreement with Morgan Stanley - TipRanks
Form 424B5 Immix Biopharma, Inc. - StreetInsider
Immix Biopharma’s Market Dynamics Amid Economic Shifts - timothysykes.com
Immix Soars On NXC-201 Data In Relapsed/Refractory AL Amyloidosis; BLA Planned For 2026 - Nasdaq
Immix Biopharma Prices $100 Million Offering - marketscreener.com
Immix Biopharma Announces Positive Phase 2 Trial Results - TipRanks
Form FWP Immix Biopharma, Inc. Filed by: Immix Biopharma, Inc. - StreetInsider
Immix Biopharma, Inc. Announces Positive Phase 2 NXC-201 Results - TradingView — Track All Markets
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - The Manila Times
Immix Biopharma prices $100 million public offering to fund AL amyloidosis drug - Investing.com Nigeria
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):